Dementia: New criteria but no new treatments

The Lancet Neurology

Volumn 11, Issue 1, 2012, Pages 4-5

  Sperling, Reisa A ^a   Johnson, Keith A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; FLORBETAPIR F 18; FLUTEMETAMOL F 18; GAMMA SECRETASE INHIBITOR; PITTSBURGH COMPOUND B; SEMEGASTAT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL RESEARCH; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DISEASE COURSE; DRUG FATALITY; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; NERVE DEGENERATION; NEUROPATHOLOGY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SKIN CANCER;

AGING; DEMENTIA; HUMANS; MILD COGNITIVE IMPAIRMENT;

EID: 83455187954     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70272-1     Document Type: Note

References (11)

1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
2. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
4. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
5. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
6. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir PET for imaging B-amyloid pathology. JAMA 2011, 305:275-283.
7. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011, 68:1398-1403.
8. Siemers E, Henley D, Sundell K, et al. Evaluating semagacestat, a gammasecretase inhibitor, in a phase III trial. Alzheimers Dement 2011, 7(suppl):S484-S485. (PL-03-02).
9. Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011, 77:1253-1262.
10. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2011, published online Oct 10. 10.1001/archneurol.2011.1538.
11. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9:363-372.